Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Thomas Powles(Queen Mary University of London), Craig B. Davis(National Institutes of Health), Keith A. Ching(Pfizer (United States)), Rosa Tambaro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Petros Grivas(Seattle Cancer Care Alliance), Yohann Loriot(Institut Gustave Roussy), Xinmeng Jasmine Mu(Pfizer (United States)), Carlos Álvarez-Fernández(Instituto de Investigación Sanitaria del Principado de Asturias), Srikala S. Sridhar(Princess Margaret Cancer Centre), Daniel P. Petrylak(Yale University), Joaquim Bellmunt(Dana-Farber Cancer Institute), Maureen J.B. Aarts(Maastricht University Medical Centre), Louis Marie Dourthe, Jie Pu(Pfizer (United States)), Alessandra di Pietro(Inserm), Cora N. Sternberg(Cornell University)
Cited by 115
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Identification of a major co-receptor for primary isolates of HIV-1
|Nature|1996|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k